Jürgen Harder

Prof. Jürgen Harder


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2005 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
JHJürgen Harder
Jürgen Harder
JSJens-Michael Schröder
Jens-Michael Schröder
Patients with psoriasis, a chronic, hyperproliferative and noninfectious skin disease, suffer surprisingly fewer cutaneous infections than would be expected. This observation led us to the hypothesis that a local “chemical shield” in the form of antimicrobial proteins provides psoriatic skin with resistance against infection. We subsequently began a systematic analysis of in vitro antimicrobially active proteins in psoriatic-scale extracts. A biochemical approach with rigorous purification and characterization combined with antimicrobial testing identified a number of mostly new human antibiotic peptides and proteins. In this review, we will focus on the most prominent antimicrobial proteins in psoriatic-scale extracts, which we identified as the S100-protein psoriasin, human β-defensin 2 (hBD-2), RNase 7, lysozyme, and human neutrophil defensin 1–3. Apart from these cutaneous, antimicrobial proteins, only a few others, including hBD-3, have been characterized. A great number of minor antimicrobial proteins await further structural characterization.

1 September 2004 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JHJürgen Harder
Jürgen Harder
UMUlf Meyer-Hoffert
Ulf Meyer-Hoffert
KWKai Wehkamp
Kai Wehkamp
LSLars Schwichtenberg
Lars Schwichtenberg
JSJens-Michael Schröder
Jens-Michael Schröder

3 March 2008 in BMC Urology
Verified
Journal Article
Open access
PDF file
HSHenrik Suttmann
Henrik Suttmann
MRMargitta Retz
Margitta Retz
FPFriedrich Paulsen
Friedrich Paulsen
JHJürgen Harder
Jürgen Harder
UZUlrike Zwergel
Ulrike Zwergel
JLJan Lehmann
Jan Lehmann
This study evaluated the cytotoxic and antiproliferative efficacy of two well-characterized members of the Cecropin-family of antimicrobial peptides against bladder tumor cells and benign fibroblasts. The antiproliferative and cytotoxic potential of the Cecropins A and B was quantified by colorimetric WST-1-, BrdU- and LDH-assays in four bladder cancer cell lines as well as in murine and human fibroblast cell lines. IC50 values were assessed by logarithmic extrapolation, representing the concentration at which cell viability was reduced by 50%. Scanning electron microscopy (SEM) was performed to visualize the morphological changes induced by Cecropin A and B in bladder tumor cells and fibroblasts. Cecropin A and B inhibit bladder cancer cell proliferation and viability in a dose-dependent fashion. The average IC50 values of Cecropin A and B against all bladder cancer cell lines ranged between 73.29 μg/ml and 220.05 μg/ml. In contrast, benign fibroblasts were significantly less or not at all susceptible to Cecropin A and B. Both Cecropins induced an increase in LDH release from bladder tumor cells whereas benign fibroblasts were not affected. SEM demonstrated lethal membrane disruption in bladder cancer cells as opposed to fibroblasts. Cecropin A and B exert selective cytotoxic and antiproliferative efficacy in bladder cancer cells while sparing targets of benign murine or human fibroblast origin. Both peptides may offer novel therapeutic strategies for the treatment of bladder cancer with limited cytotoxic effects on benign cells.

4 October 2012 in Experimental Dermatology
Verified
Journal Article
Open access
PDF file
JHJürgen Harder
Jürgen Harder
JSJens‐Michael Schröder
Jens‐Michael Schröder
RGRegine Gläser
Regine Gläser
Human skin protects the body as an outer barrier from various environmental threats and has to deal with an immense quantity of microbes comprising members of the own microbiota as well as potential pathogenic microbes. In this viewpoint, we highlight important cutaneous first‐line defense barriers from the perspective of a microbe that tries to colonize and invade human skin. We place special emphasis on the role of antimicrobial peptides and the microbiota. In addition, we discuss and try to provide answers to some emerging issues concerning the various defense strategies of the epidermis.

29 July 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BKBente Köten
Bente Köten
MSMaren Simanski
Maren Simanski
RGRegine Gläser
Regine Gläser
RPRainer Podschun
Rainer Podschun
JSJens-Michael Schröder
Jens-Michael Schröder
JHJürgen Harder
Jürgen Harder
Human skin is able to mount a fast response against invading microorganisms by the release of antimicrobial proteins such as the ribonuclease RNase 7. Because RNase 7 exhibits high activity against Enterococcus faecium the aim of this study was to further explore the role of RNase 7 in the cutaneous innate defense system against E. faecium. Absolute quantification using real-time PCR and ELISA revealed that primary keratinocytes expressed high levels of RNase 7. Immunohistochemistry showed RNase 7 expression in all epidermal layers of the skin with an intensification in the upper more differentiated layers. Furthermore, RNase 7 was secreted by keratinocytes in vitro and in vivo in a site-dependent way. RNase 7 was still active against E. faecium at low pH (5.5) or high NaCl (150 mM) concentration and the bactericidal activity of RNase 7 against E. faecium required no ribonuclease activity as shown by recombinant RNase 7 lacking enzymatic activity. To further explore the role of RNase 7 in cutaneous defense against E. faecium, we investigated whether RNase 7 contributes to the E. faecium killing activity of skin extracts derived from stratum corneum. Treatment of the skin extract with an RNase 7 specific antibody, which neutralizes the antimicrobial activity of RNase 7, diminished its E. faecium killing activity. Our data indicate that RNase 7 contributes to the E. faecium-killing activity of skin extracts and suggest an important role for RNase 7 in the protection of human skin against E. faecium colonization.

1 December 2007 in Innate Immunity
Verified
Journal Article
Closed access
PDF file
JHJürgen Harder
Jürgen Harder
RGRegine Gläser
Regine Gläser
JSJens-Michael Schröder
Jens-Michael Schröder
We live in a world populated by an enormous number of micro-organisms. This necessitates the existence of highly effective mechanisms to control microbial growth. Through many research efforts, a chemical defense system based on the production of antimicrobial proteins (AMPs) has been identified. AMPs are endogenous, small proteins exhibiting antimicrobial activity against a wide variety of micro-organisms. The wide distribution of these molecules in the plant and animal kingdom reflects their biological significance. Various human AMPs show a potent effect on pathogenic micro-organisms including antibiotic-resistant bacteria. Thus, there is great interest in understanding the role of AMPs within innate immunity and evaluating their use and/or specific induction to fend off infections. In this review, we provide an overview of the characteristics of human AMPs and discuss examples where AMPs may be involved in the pathogenesis of infectious and inflammatory diseases.